Scholarlink

<p>Osteoporosis can often develop following cancer therapy. Treatments that lead to hypogonadism are by far the primary cause, especially endocrine therapies for breast and prostate cancer, but also treatments that lead to permanent gonadal damage. It is possible to diagnose and manage cancer treatment-induced bone loss. From the oncology perspective, these long-term side effects should not be neglected. The success of new treatment methods has led to significant improvements in survival rates, thus, increasing the risk of osteoporosis in later years in combination with treatment-induced decreases in bone mass. Oncologists should be aware of the risks of developing bone loss to take early prophylactic or therapeutic measures. In this article, treatment-related complications are summarized.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prävention und Behandlung der tumor- und tumortherapie-induzierten Osteoporose

  • 期刊论文

  • 发表日期：

    2026年1月3日

查看全文
  • Ingo J. Diel

摘要

Osteoporosis can often develop following cancer therapy. Treatments that lead to hypogonadism are by far the primary cause, especially endocrine therapies for breast and prostate cancer, but also treatments that lead to permanent gonadal damage. It is possible to diagnose and manage cancer treatment-induced bone loss. From the oncology perspective, these long-term side effects should not be neglected. The success of new treatment methods has led to significant improvements in survival rates, thus, increasing the risk of osteoporosis in later years in combination with treatment-induced decreases in bone mass. Oncologists should be aware of the risks of developing bone loss to take early prophylactic or therapeutic measures. In this article, treatment-related complications are summarized.